Physician profile
Robert W Veith
NPI 1750384921
$8,557.46
in general payments reported to CMS, 2019-2025
67 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $615 · 2021: $1,156 · 2022: $2,502 · 2023: $956 · 2024: $653 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,909.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $752.22 | 2019-2025 | |
| Janssen Biotech, INC. | $666.88 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Pfizer INC. | $460.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $454.58 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $428.48 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Daiichi Sankyo INC. | $387.76 | 2020-2025 | Enhertu, Vanflyta, Injectafer |
| Astrazeneca Pharmaceuticals LP | $363.12 | 2019-2025 | Enhertu |
| Incyte Corporation | $295.19 | 2019-2023 | Monjuvi, Jakafi |
| Genzyme Corporation | $288.88 | 2019-2025 | |
| Amgen INC. | $254.27 | 2019-2022 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Celgene Corporation | $225.59 | 2019-2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $212.38 | 2019-2023 | |
| Genentech USA, INC. | $164.11 | 2021-2023 | Venclexta |
| Exelixis INC. | $156.09 | 2021-2025 | Cabometyx |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Veith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.